BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31103265)

  • 21. Long non-coding RNA T-cell factor 7 in multiple myeloma: A potential biomarker for deteriorated clinical features and poor prognosis.
    Zhang C; Chu M; Fan Y; Wu L; Li Z; Ma X; Zhuang W
    J Clin Lab Anal; 2020 Sep; 34(9):e23400. PubMed ID: 32578294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF.
    Bianchi E; Bulgarelli J; Ruberti S; Rontauroli S; Sacchi G; Norfo R; Pennucci V; Zini R; Salati S; Prudente Z; Ferrari S; Manfredini R
    Cell Death Differ; 2015 Dec; 22(12):1906-21. PubMed ID: 25857263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
    Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
    Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
    Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance.
    Alonso S; Hernandez D; Chang YT; Gocke CB; McCray M; Varadhan R; Matsui WH; Jones RJ; Ghiaur G
    J Clin Invest; 2016 Dec; 126(12):4460-4468. PubMed ID: 27775549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance.
    Caillot M; Zylbersztejn F; Maitre E; Bourgeais J; Hérault O; Sola B
    Cells; 2020 Oct; 9(11):. PubMed ID: 33114738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulation of long non-coding RNA XIST inhibits cell proliferation, migration, invasion and EMT by regulating miR-212-3p/CBLL1 axis in non-small cell lung cancer cells.
    Qiu HB; Yang K; Yu HY; Liu M
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8391-8402. PubMed ID: 31646569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
    Jia C; Kong D; Guo Y; Li L; Quan L
    Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lnc-NTF3-5 promotes osteogenic differentiation of maxillary sinus membrane stem cells via sponging miR-93-3p.
    Peng W; Zhu SX; Wang J; Chen LL; Weng JQ; Chen SL
    Clin Implant Dent Relat Res; 2018 Apr; 20(2):110-121. PubMed ID: 29106055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Apg-1 in HSF1 activation and bortezomib sensitivity in myeloma cells.
    Zhu M; Huang Y; Tang J; Shao S; Zhang L; Zhou Y; He S; Wang Y
    Exp Hematol; 2020 Jan; 81():50-59. PubMed ID: 31899217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
    Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
    Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.
    Zheng Z; Fan S; Zheng J; Huang W; Gasparetto C; Chao NJ; Hu J; Kang Y
    J Hematol Oncol; 2018 Feb; 11(1):29. PubMed ID: 29482577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
    Hurt EM; Wiestner A; Rosenwald A; Shaffer AL; Campo E; Grogan T; Bergsagel PL; Kuehl WM; Staudt LM
    Cancer Cell; 2004 Feb; 5(2):191-9. PubMed ID: 14998494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR-218 contributes to drug resistance in multiple myeloma via targeting LRRC28.
    Chen H; Cao W; Chen J; Liu D; Zhou L; Du F; Zhu F
    J Cell Biochem; 2021 Apr; 122(3-4):305-314. PubMed ID: 33417267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of XIST facilitates cell proliferation, invasion and suppresses cell apoptosis by reducing radio-sensitivity of glioma cells via miR-329-3p/CREB1 axis.
    Wang YP; Li HQ; Chen JX; Kong FG; Mo ZH; Wang JZ; Huang KM; Li XN; Yan Y
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3190-3203. PubMed ID: 32271437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.
    Yuan X; Ma R; Yang S; Jiang L; Wang Z; Zhu Z; Li H
    Cell Cycle; 2019 Jul; 18(14):1660-1669. PubMed ID: 31204563
    [No Abstract]   [Full Text] [Related]  

  • 38. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
    Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
    J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.
    Li Z; Wang H; Wang Y; Ma Z; Hu L; Luo S; Gong Y; Zhu L; Gong H; Xiang R; Zhu Y; Xie Y; Yang C; Peng H; Liu J; Xiao X
    Cancer Lett; 2023 Feb; 554():216019. PubMed ID: 36442773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway.
    Wu Y; Wang H
    J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29205703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.